SI-BONE, Inc. reported a 27% increase in worldwide revenue for Q4 2022, reaching $32.0 million. U.S. revenue increased by 28% to $30.0 million. The company's net loss was $11.2 million, or $0.32 per diluted share, and the adjusted EBITDA loss improved by 54% to $4.2 million.
Worldwide revenue increased by 27% to $32.0 million compared to the prior year period.
U.S. revenue grew by 28% to $30.0 million, driven by domestic case volumes.
Gross margin was 84%, impacted by lower average selling prices and higher costs.
Net loss improved to $11.2 million, or $0.32 per diluted share, compared to $14.5 million in the prior year period.
SI-BONE expects 2023 worldwide revenue of approximately $124 million to $127 million, representing growth of approximately 17% to 19% compared to fiscal year 2022. SI-BONE also anticipates that gross margin will be approximately 80% for fiscal year 2023 and Adjusted EBITDA loss will continue to improve year over year in 2023.
Visualization of income flow from segment revenue to net income